OBJECTIVES: To present a two-year update on RW data available from a patient registry of patients with multiple sclerosis (MS) being treated with cladribine tablets in Portugal.

METHODS: Anonymized data was retrieved from a patient support program database of MS patients currently being treated with cladribine tablets in Portugal. Data was checked for missing values and descriptive analysis was run for the available information using STATA17. For all parameters missing data was censured, with number of samples being mentioned. Information was available from a total of 28 hospitals. Cut-off date for the analysis was May 20^th, 2022.

RESULTS: Since last cut-off in 2020, 146 new patients were enrolled for a total of 234 patients. On the same period 13 patients switched treatment, 6 for ocrelizumab, 3 for natalizumab, 2 for interferon-beta1a 44 mg and 2 for drug unknown. 74,8% of the whole population were female. Average age at time of cut-off for the population on-treatment was 42,17 ± 12,18 years, with a median of 41 years, and a minimum of 21 and a maximum of 76 years. The average time on treatment (ToT) with cladribine tablets for the whole population (n=234) was 590 ± 383 days, with a median of 541 days, and a minimum of 3 days and a maximum of 1.423 days. For patients that dropped-out of treatment (n=13) average ToT was 682 ± 244 days, with a median of 729 days, and a minimum of 347 days and a maximum of 1.117 days. For the population currently on treatment (n=221) the average ToT was 585 ± 390 days, with a median of 522 days.

CONCLUSIONS: Data observed seems to validate the long-term ToT for cladribine tablets, in line with what has been observed in randomized-controlled trials and also in other RW studies.